OP-28. Treatment of lymphoid cell malignancy with 114Inm-labelled autologous lymphocytes

Sharma, H.L.; Cowan, Richard A; Murby, Brian; Owens, Susan E; Nuttall, P; Gunton, D.; Smith, Alexander M.; Chang, James; Crowther, Derek

doi:10.1097/00006231-199705000-00059

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The contaminating platelets and plasma were removed by three sequential washes and resuspensions of the cell pellet in isotonic saline, followed by centrifugation at 100 g . Lymphocytes were then labelled with 114m In oxine by incubation at room temperature for 15 min (Sharma et al , 1997), at a final concentration ranging from 6 to 25 MBq per 10 9 cells. Unbound 114m In oxine was removed by addition of autologous platelet‐free plasma.…”

Section: Preparation Of Lymphocyte Suspensions and Labelling With Indmentioning

confidence: 99%

“…Pharmacokinetic studies have demonstrated a consistent 70–80% uptake of 114m In in the liver and spleen, and approximately 5% uptake in the bone marrow (Hamilton et al , 1988). Preliminary clinical studies with 114m In‐labelled lymphocytes have demonstrated a marked anticancer effect in patients with refractory CLL (Sharma et al , 1997). In this report, we describe the results of a phase I–II study of 114m In‐labelled autologous lymphocytes in patients with resistant end‐stage disease.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Autologous lymphocytes as vectors to target therapeutic radiation, using indium‐114m, in patients with lymphoid cell malignancy

Cowan¹,

Murby

Gunton

et al. 2002

Br J Haematol

View full text Add to dashboard Cite

Summary. Autologous lymphocytes provide a potential vector for the delivery of a cytotoxic agent in patients with lymphoid cell malignancy. This report describes a phase I–II study using autologous lymphocytes to target the radionuclide indium‐114m (114mIn) in patients with refractory chronic lymphocytic leukaemia or small lymphocytic non‐Hodgkin's lymphoma. Nineteen patients, the majority of whom had been heavily pretreated with conventional chemotherapy and radiotherapy, received between 69 and 211 MBq 114mIn‐labelled autologous lymphocytes. Approximately 80% of the administered activity was localized in the liver and spleen, with around 5% accumulating in the bone marrow. Ten patients (53%) responded (one complete response and nine partial responses). The median duration of response was 7 months. The median survival for the responders was 14 months and for the non‐responders was 3 months. The first notable response in every patient was a fall in peripheral lymphocyte count. The indium treatment was not associated with any subjective toxicity, although all patients suffered from myelosuppression, with thrombocytopenia being the dose‐limiting factor. This study has demonstrated a significant anti‐tumour effect in a group of patients with late‐stage highly resistant disease.

show abstract

Section: Preparation Of Lymphocyte Suspensions and Labelling With Indmentioning

confidence: 99%

mentioning

confidence: 99%

Autologous lymphocytes as vectors to target therapeutic radiation, using indium‐114m, in patients with lymphoid cell malignancy

Cowan¹,

Murby

Gunton

et al. 2002

Br J Haematol

View full text Add to dashboard Cite

show abstract

OP-28. Treatment of lymphoid cell malignancy with 114Inm-labelled autologous lymphocytes

Cited by 1 publication

References 0 publications

Autologous lymphocytes as vectors to target therapeutic radiation, using indium‐114m, in patients with lymphoid cell malignancy

Autologous lymphocytes as vectors to target therapeutic radiation, using indium‐114m, in patients with lymphoid cell malignancy

Contact Info

Product

Resources

About